EUVIMEDEUVIMED entdecken
Crossref

Cross‐Sectional and Longitudinal Diagnostic Performance of Plasma p‐tau217 and p‐tau217/Aβ42 in Alzheimer's Disease

Mingxing Jiang, Guoyu Lan, Jiayi Zhu, Laihong Zhang, Anqi Li, Zhengbo He, Yalin Zhu, Xin Zhou, Li Liang, Na Gao, Pan Sun, Yue Cai und 11 weitere

Annals of Neurology · 2026

DOI: 10.1002/ana.78322 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Neurology, 2026. Verfasst von Mingxing Jiang und 22 weiteren Autor:innen. Beteiligte Einrichtung: Shenzhen Medical Academy of Research and Translation, Shenzhen, China. Hauptthemen laut MEDLINE: tau Proteins, Alzheimer Disease, Amyloid beta-Peptides, Peptide Fragments. Die Arbeit nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Recent studies suggest that combining plasma phosphorylated tau (p‐tau) with β ‐amyloid (A β ) may improve diagnosis accuracy for Alzheimer's disease (AD). However, the cross‐sectional and longitudinal concordance of these markers with A β positron emission tomography (PET) positivity remains incompletely understood. This study aimed to evaluate the diagnostic performance of plasma p‐tau, alone and in combination with plasma A β , in AD.

Methods

We included 326 participants from the Alzheimer's Disease Neuroimaging Initiative and 357 Chinese older adults from the Greater‐Bay‐Area Healthy Aging Brain Study who underwent A β ‐PET imaging. Longitudinal data were available for 285 Alzheimer's Disease Neuroimaging Initiative participants. Plasma p‐tau181, p‐tau217, A β 42, and A β 40 were measured on different analytical platforms. Diagnostic performance for A β ‐PET positivity was assessed using a two‐cutoff approach.

Results

Combining plasma p‐tau with A β 42 or the A β 42/40 ratio reduced the intermediate zone. Notably, p‐tau217/A β 42 showed stronger agreement with A β ‐PET positivity than p‐tau217 alone. Among individuals classified as p‐tau217/A β 42 positive but p‐tau217 intermediate, 57.1 to 83.3% were A β ‐PET positive. Longitudinally, most Stable Positive (88.0–96.1%) and Stable Negative (89.4–90.9%) cases defined by p‐tau217 or p‐tau217/A β 42 were A β ‐PET positive and A β ‐PET negative, respectively. Critically, 69.7 to 75.8% of Non‐positive to Positive cases defined by p‐tau217/A β 42 were A β ‐PET positive.

Interpretation

These findings provide novel insights into the cross‐sectional and longitudinal diagnostic performance of plasma p‐tau217/A β 42 in AD. To be specific, plasma p‐tau217/A β 42 can reduce the intermediate zone and improve agreement with A β ‐PET positivity, and longitudinal p‐tau217/A β 42 monitoring is particularly informative for identifying A β ‐PET–positive patients who were p‐tau217/A β 42 negative or intermediate at baseline and were misclassified as low risk of AD. ANN NEUROL 2026;100:998–1011

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

tau ProteinsAlzheimer DiseaseAmyloid beta-PeptidesPeptide FragmentsHumansCross-Sectional StudiesFemaleLongitudinal StudiesAgedPositron-Emission TomographyMaleBiomarkersPhosphorylationAged, 80 and over

Substanzen

tau ProteinsAmyloid beta-PeptidesPeptide Fragmentsamyloid beta-protein (1-42)BiomarkersMAPT protein, human

Autor:innen und Institutionen

  • Shenzhen Medical Academy of Research and Translation, Shenzhen, China.
  • Westlake University, Hangzhou, China.
  • Institute of Neurological and Psychiatric Disorders, Shenzhen Bay Laboratory, Shenzhen, China.
  • School of Biology and Biological Engineering, South China University of Technology, Guangzhou, China.
  • School of Life Science and Technology, Harbin Institute of Technology, Harbin, China.
  • Division of Life Science, The Hong Kong University of Science and Technology, Hong Kong, China.

ORCID-Profile: Tengfei Guo

Zitieren

APA

Jiang, M., Lan, G., Zhu, J., Zhang, L., Li, A., He, Z., Zhu, Y., Zhou, X., Liang, L., Gao, N., Sun, P., Cai, Y., Fan, X., Chen, X., Shi, D., Liu, Z., Wang, Q., Cheng, G., Wang, L., …, & Guo, T. (2026). Cross‐Sectional and Longitudinal Diagnostic Performance of Plasma p‐tau217 and p‐tau217/Aβ42 in Alzheimer's Disease. Annals of Neurology. https://doi.org/10.1002/ana.78322

Vancouver

Jiang M, Lan G, Zhu J, Zhang L, Li A, He Z, et al. Cross‐Sectional and Longitudinal Diagnostic Performance of Plasma p‐tau217 and p‐tau217/Aβ42 in Alzheimer's Disease. Annals of Neurology. 2026. doi:10.1002/ana.78322

BibTeX
@article{Jiang2026,
  author = {Jiang, Mingxing and Lan, Guoyu and Zhu, Jiayi and Zhang, Laihong and Li, Anqi and He, Zhengbo and Zhu, Yalin and Zhou, Xin and Liang, Li and Gao, Na and Sun, Pan and Cai, Yue and Fan, Xiang and Chen, Xuhui and Shi, Dai and Liu, Zhen and Wang, Qingyong and Cheng, Guanxun and Wang, Lu and Alzheimer's Disease Neuroimaging Initiative, Alzheimer's Disease Neuroimaging Initiative and Dong, Mengjie and Wang, Yan-Jiang and Guo, Tengfei},
  title = {Cross‐Sectional and Longitudinal Diagnostic Performance of Plasma p‐tau217 and p‐tau217/Aβ42 in Alzheimer's Disease},
  journal = {Annals of Neurology},
  year = {2026},
  doi = {10.1002/ana.78322}
}
Kostenlos starten →